Karen S Sfanos
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (18)
Background Gene fusions are hybrid genes that arise from chromosomal rearrangements linking two independent genes. The most common gene fusion in prostate cancer involves the 5′ androgen‐regulated TMPRSS2 promoter fused with the 3′ ETS transcription factor ERG. TMPRSS2:ERG (T:E) gene fusions occur in about half of all prostate cancers and are considered an early event in oncogenesis. Investigations into the mechanism behind T:E gene fusion initiation using in vitro systems are hindered by the technical limitations posed by fluorescence in situ hybridization and suboptimal sensitivity of reverse transcription quantitative PCR (RT‐qPCR). The objective of this study was to develop a reliable, user‐friendly method of detecting low‐abundance T:E gene fusion transcripts as a read‐out for putative T:E gene fusions generated in cells. Methods We assessed the sensitivity of droplet digital PCR (ddPCR) by quantifying T:E gene fusion transcripts using gene fragment‐ or cell‐based standard curves. Next, we evaluated dihydrotestosterone (DHT), genotoxic insults (irradiation, etoposide), and inflammatory agents tumor necrosis factor‐alpha (TNF‐α) and hydrogen peroxide (H 2 O 2 ) as initiators of T:E fusions in a fusion‐negative prostate cell line (LNCaP). Finally, we performed RT‐qPCR to measure the expression of androgen receptor ( AR ), AR‐regulated genes ( TMPRSS2, NKX3.1 ) and the downstream activation target of TNF‐α, NF‐κB . Results We identified ddPCR as a sensitive method for detecting rare T:E gene fusion transcripts and observed consistent detection in reactions containing a single T:E gene fragment, or 1 fusion‐positive cell per 10,000 fusion‐negative cells. Consistent with prior studies, the ddPCR assay identified DHT combined with etoposide as potent, synergistic initiators of T:E gene fusion transcript expression in LNCaP cells. We did not detect T:E gene fusion transcripts after LNCaP exposure to irradiation, TNF‐α, or H 2 O 2 . We determined that TNF‐α and H 2 O 2 exposure led to global downregulation of AR signaling, which may have limited the formation or expression of treatment‐initiated genomic T:E fusions. Therefore, one limitation of the ddPCR assay is the requirement for T:E fusion mRNA expression. Conclusions Our proposed method significantly improves the feasibility of testing novel initiators of the T:E gene fusion and can be applied to additional studies investigating mechanisms of gene fusion initiation in prostate and other cancers.
Year:
2025
Background Many patients with biochemically recurrent prostate cancer (BCRPC) prefer to delay androgen deprivation therapy (ADT) due to its adverse effects, highlighting the need for better‐tolerated, effective alternatives. A subgroup analysis of our prior Phase II trial showed that muscadine grape skin extract (MPX) increased PSA doubling time (PSADT) in patients with SOD2 Ala/Ala variant which provided the rationale for this trial. Methods This randomized, double‐blind, placebo‐controlled trial, conducted at 14 sites, evaluated patients with BCRPC and SOD2 Ala/Ala genotype. Patients received 4000 mg MPX or placebo daily. The primary endpoint was on‐study PSA slope with comparisons between treatment arms. Secondary endpoints were PSADT, PSA response (≥ 50% decrease), and PSA progression free survival (PFS). Correlative studies included markers of oxidative stress and gastrointestinal microbiota composition. Results At interim analysis, fifty‐nine patients were randomized (MPX, n = 29; placebo, n = 30). On‐study PSA slopes at 12, 24, 36, and 48 weeks showed no significant differences between the MPX and placebo arms ( p = 0.49). The study was stopped due to futility. No significant differences were observed in PSADT, PSA response, median PSA PFS, or oxidative stress biomarkers. MPX was well‐tolerated, with no grade 3–4 AEs attributable to the study drug. Microbiome analysis showed no significant differences in alpha diversity but revealed increased relative abundance of Roseburia faecis and Akkermansia muciniphila in the MPX group. Conclusions Although MPX supplementation had no significant effect on PSA slope in men with BCRPC and SOD2 Ala/Ala variant, this study provides a rigorous evaluation of a natural product and highlights the importance of well‐designed clinical trials in advancing evidence‐based integrative oncology. Trial registration ClinicalTrials. gov, NCT03535675.
Year:
2025
Gene fusions are hybrid genes that arise from chromosomal rearrangements linking two independent genes. The most common gene fusion in prostate cancer involves the 5’ androgen-regulated TMPRSS2 promoter fused with the 3’ ETS transcription factor ERG. TMPRSS2:ERG (T:E) gene fusions occur in about half of all prostate cancers and are considered an early event in oncogenesis. Investigations into the mechanism behind T:E gene fusion initiation using in vitro systems are hindered by the technical limitations posed by fluorescence in situ hybridization and suboptimal sensitivity of reverse transcription quantitative PCR. The objective of this study was to develop a reliable, user-friendly method of detecting low abundance T:E gene fusion transcripts as a read-out for putative T:E gene fusions generated in cells. We identified droplet digital PCR (ddPCR) as a sensitive method for detecting rare T:E gene fusion transcripts and observed consistent detection in reactions containing a single T:E gene fragment, or 1 fusion positive cell per 10,000 fusion negative cells. Next, we evaluated dihydrotestosterone (DHT), genotoxic insults (irradiation, etoposide), and inflammatory agents tumor necrosis factor-alpha (TNFα) and hydrogen peroxide (H 2 O 2 ) as initiators of T:E fusions in a fusion negative prostate cell line (LNCaP). Consistent with prior studies, we identified DHT combined with etoposide as potent, synergistic initiators of T:E gene fusion transcript expression in LNCaP cells. We did not detect T:E gene fusion transcripts after LNCaP exposure to irradiation, TNFα, or H 2 O 2 . We determined that TNFα and H 2 O 2 exposure led to global downregulation of androgen receptor signaling, which may have limited the formation or expression of treatment-initiated genomic T:E fusions. Therefore, one limitation of the ddPCR assay is the requirement for T:E fusion mRNA expression. Our proposed method significantly improves the feasibility of testing novel initiators of the T:E gene fusion and can be applied to additional studies investigating mechanisms of gene fusion initiation in prostate and other cancers.
Year:
2025
FASN protein expression is increased in prostate tumors from germline HOXB13 G84E carriers compared with matched WT controls. A, FASN protein expression by immunostaining is higher in HOXB13 G84E carriers than matched HOXB13 WT controls. B, ERG status is not associated with FASN protein expression among HOXB13 G84E carriers, though higher expression is seen among ERG-positive compared with ERG-negative tumors from HOXB13 WT controls (****, P
Year:
2024
Neither FASN protein, nor FASN gene methylation are associated with self-identified race. A, FASN protein expression by race in JHU primary tumor cohort. B, FASN protein expression by race in PCBN primary tumor cohort. C, FASN protein expression by race in TCGA primary tumor cohort. D, FASN gene expression by race in TCGA primary tumor cohort. E, FASN gene methylation mean beta value by self-identified race in JHU primary tumor cohort. F, FASN gene methylation mean beta value by self-identified race in TCGA primary tumor cohort (*, P
Year:
2024
FASN protein expression in tumor glands is inversely correlated with FASN gene methylation in tumor tissue in metastatic CRPC cohort. A, Representative plots of CpG methylation level in FASN by WGBS with corresponding FASN mRNA expression (TPM) for three representative tumors with low (blue) and high (red) FASN gene expression in the SU2C WCDT cohort. Mean FASN CpG methylation level is negatively correlated with FASN mRNA expression in the SU2C WCDT samples; each point represents an individual tumor in B .
Year:
2024
FASN protein expression in tumor glands is inversely correlated with FASN gene methylation in tumor tissue in primary prostate tumors. A, Representative plots of beta values (range: 0–1) by FASN probe on InfiniumEPIC for three tumors among the lowest (blue, H-score range from 3–4) and highest (red, H-score range from 289–292) mean FASN protein expression in the JHU cohort. Mean FASN beta values are negatively correlated with FASN protein levels by immunostaining for tumors in JHU cohort ( B ) and with FASN protein levels by RPPA in TCGA cohort ( C ). Each point in B and C represents an individual tumor.
Year:
2024
Neither FASN protein, nor FASN gene methylation are associated with self-identified race. A, FASN protein expression by race in JHU primary tumor cohort. B, FASN protein expression by race in PCBN primary tumor cohort. C, FASN protein expression by race in TCGA primary tumor cohort. D, FASN gene expression by race in TCGA primary tumor cohort. E, FASN gene methylation mean beta value by self-identified race in JHU primary tumor cohort. F, FASN gene methylation mean beta value by self-identified race in TCGA primary tumor cohort (*, P
Year:
2024
Fatty acid synthase (FASN) catalyzes the synthesis of long-chain saturated fatty acids and is overexpressed during prostatic tumorigenesis, where it is the therapeutic target in several ongoing trials. However, the mechanism of FASN upregulation in prostate cancer remains unclear. Here, we examine FASN gene CpG methylation pattern by InfiniumEPIC profiling and whole-genome bisulfite sequencing across multiple racially diverse primary and metastatic prostate cancer cohorts, comparing with FASN protein expression as measured by digitally quantified IHC assay and reverse phase protein array analysis or FASN gene expression. We demonstrate that the FASN gene body is hypomethylated and overexpressed in primary prostate tumors compared with benign tissue, and FASN gene methylation is significantly inversely correlated with FASN protein or gene expression in both primary and metastatic prostate cancer. Primary prostate tumors with ERG gene rearrangement have increased FASN expression and we find evidence of FASN hypomethylation in this context. FASN expression is also significantly increased in prostate tumors from carriers of the germline HOXB13 G84E mutation compared with matched controls, consistent with a report that HOXB13 may contribute to epigenetic regulation of FASN in vitro . However, in contrast to previous studies, we find no significant association of FASN expression or methylation with self-identified race in models that include ERG status across two independent primary tumor cohorts. Taken together, these data support a potential epigenetic mechanism for FASN regulation in the prostate which may be relevant for selecting patients responsive to FASN inhibitors. Significance: Here, we leverage multiple independent primary and metastatic prostate cancer cohorts to demonstrate that FASN gene body methylation is highly inversely correlated with FASN gene and protein expression. This finding may shed light on epigenetic mechanisms of FASN regulation in prostate cancer and provides a potentially useful biomarker for selecting patients in future trials of FASN inhibitors.
Year:
2024
FASN protein expression is increased in prostate tumors from germline HOXB13 G84E carriers compared with matched WT controls. A, FASN protein expression by immunostaining is higher in HOXB13 G84E carriers than matched HOXB13 WT controls. B, ERG status is not associated with FASN protein expression among HOXB13 G84E carriers, though higher expression is seen among ERG-positive compared with ERG-negative tumors from HOXB13 WT controls (****, P
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (10)
Ginger Milne
Professor with Tenure
Vanderbilt University Medical Center
Channing Paller
Johns Hopkins University
Tamara L. Lotan
Professor
Johns Hopkins University
Adam Sowalsky
Senior Investigator
National Cancer Institute
Catherine Marshall
Associate Professor
Johns Hopkins University School of Medicine
Michael Haffner
Fred Hutchinson Cancer Research Center
Elisabeth I. Heath
Wayne State University School of Medicine
Corinne Joshu
Johns Hopkins University
Emmanuel S. Antonarakis
-
Angelo De Marzo
Professor
Johns Hopkins University School of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.